Vaxart, Inc. (VXRT) bonds
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Vaxart reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Vaxart's 10-K for the period ended Feb 13, 2018
Vaxart's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| Loan Agreement | – | $5.00M |
See a number that looks wrong?